Apotex Pty Ltd v ICOS Corporation (No 3)

Link copied
Case Copied 69 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v ICOS Corporation (No 3) [2018] FCA 1204

File number: VID 280 of 2016
Judge: BESANKO J
Date of judgment: 14 August 2018
Catchwords:

PATENTS – where applicant seeks relief by way of declarations of invalidity and orders for revocation of claims in two patents (the 946 Patent and the 666 Patent) – where respondent is the registered owner of the two patents and denies that the claims are invalid – whether, in respect of the 946 Patent, there is a lack of inventive step, lack of novelty, the patent was obtained by false suggestion and the invention is not useful – whether, in respect of the 666 Patent, there is a lack of inventive step and a lack of novelty

PATENTS – where respondent brings a cross-claim against the applicant in which it seeks declarations to the effect that the applicant has threatened to infringe claims in the two patents – whether applicant has threatened to infringe claims in the two patents – where claims in respect of which the respondent alleges threatened infringement are the same claims which the applicant alleges are invalid – where, in respect of the two patents, the applicant admits, subject to its case on invalidity, threatened infringement in respect of certain claims – where applicant denies infringement in respect of certain claims in the two patents – where, in respect of the 666 Patent, the applicant does not admit threatened infringement of certain claims, but accepts that expert evidence establishes threatened infringement, subject to its case on invalidity

PRACTICE AND PROCEDURE – where respondent seeks injunctions, damages or an account of profits, additional damages or other relief – where issues of quantum arising from the respondent’s cross-claim be heard and determined separately from, and after, all other issues in the proceeding

Legislation:

Patents Act 1952 (Cth) s 100

Patents Act 1990 (Cth) ss 7, 12, 13, 18, 102, 105, 138

Federal Court Rules 2011 (Cth) r 30.01

Patents Regulations 1991 (Cth) reg 3.12

Cases cited:

Actavis Group Ptc EHF v ICOS Corporation [2016] EWHC 1955 (Pat)

Actavis Pty Ltd v Orion Corporation [2016] FCAFC 121

Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59; (2002) 212 CLR 411

Alcatel NV v Commissioner of Patents (1996) AIPC 91-260; (1996) 68 FCR 8

Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559; (2008) 76 IPR 618

Anaesthetic Supplies Pty Ltd v Rescare Ltd (1994) AIPC 91-076; (1994) 50 FCR 1

Apotex Pty Ltd v ICOS Corporation [2017] FCA 466

Apotex Pty Ltd v Warner‑Lambert Company LLC (No 2) [2016] FCA 1238; (2016) 122 IPR 17

AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99; (2014) 226 FCR 324

AstraZeneca AB v Apotex Pty Ltd [2015] HCA 30; (2015) 257 CLR 356

Beecham Group Limited v Bristol Laboratories Limited and Another (1978) RPC 153

Beecham Group Ltd’s (Amoxycillin) Application (1980) 97 RCP 261

CCOM Pty Ltd v Jiejing Pty Ltd (1994) AIPC 91-079;…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v ICOS Corporation (No 3) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2018] FCA 1204
Decision Date

CaseChat Overview and Summary

The case of Apotex Pty Ltd v ICOS Corporation (No 3) involves a dispute between the applicant, Apotex Pty Ltd, and the respondent, ICOS Corporation. Apotex sought relief by way of declarations of invalidity and orders for revocation of claims in two patents held by ICOS, the 946 Patent and the 666 Patent. ICOS, the registered owner of the patents, denied that the claims were invalid. The court had to decide whether there was a lack of inventive step, lack of novelty, or whether the patent was obtained by false suggestion or was not useful in respect of the 946 Patent, and whether there was a lack of inventive step and a lack of novelty in respect of the 666 Patent. Additionally, ICOS brought a cross-claim against Apotex, seeking declarations that Apotex had threatened to infringe claims in the two patents. The court had to determine whether Apotex had threatened to infringe the claims, and if so, what relief ICOS was entitled to.

The court found that Apotex had threatened to infringe all of the claims in suit in both the 946 Patent and the 666 Patent. While Apotex admitted to threatened infringement of certain claims in both patents, subject to its case on invalidity, it denied infringement in respect of other claims. Regarding the 666 Patent, Apotex did not admit threatened infringement of certain claims but accepted that expert evidence established threatened infringement, subject to its case on invalidity. The court rejected Apotex’s challenge to the validity of the patents, finding that ICOS had established that Apotex threatened to infringe the claims in suit in each patent. The issues of quantum arising from ICOS’s cross-claim were to be heard and determined separately from, and after, all other issues in the proceeding.

The court concluded that Apotex’s challenge to the validity of the 946 Patent and the 666 Patent must be rejected. ICOS had established that Apotex threatened to infringe the claims in suit in each patent. The court directed the respondent to bring in draft minutes of order reflecting the conclusions in these reasons. The entry of orders was to be dealt with in Rule 39.32 of the Federal Court Rules 2011.

Orders

Orders of the court

1. The respondent bring in draft minutes of order reflecting the conclusions in these reasons.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

For the above reasons, I conclude that Apotex threatens to infringe all of the claims in suit in the 946 Patent and in the 666 Patent.CONCLUSION Apotex’s challenge to the validity of the 946 Patent and the 666 Patent must be rejected. ICOS has established that Apotex threatens to infringe the claims in suit in the case of each patent. I will hear the parties as to the appropriate orders in light of these reasons.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.